Study Details
A Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FMS-like tyrosine kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Clinicaltrials.gov ID
Astellas Study ID
2215-CL-1101
EudraCT ID
N/A
Condition
Leukemia - AML
Phase
Phase 1
Age
18 years - N/A
Sex
Female & Male
Product
gilteritinib
Type
Interventional
Trial Dates
Jun 2019 - Jun 2021
Masking
None (Open Label)
Enrollment number
11
Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FMS-like tyrosine kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Northwestern University
Chicago, United States, 60611
The Ohio State University Comprehensive Cancer Center (OSUCCC)
Columbus, United States, 43210
Vanderbilt Ingram Cancer Center
Nashville, United States, 37232
Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC)
Charleston, United States, 29425
Roswell Park Cancer Institute (RPCI)
Buffalo, United States, 14263
Weill Cornell Medical College
New York, United States, 10065
Medical College of Wisconsin
Milwaukee, United States, 53226
University of Kentucky
Lexington, United States, 40536
University of Chicago
Chicago, United States, 60037
University of Texas MD Anderson
Houston, United States, 77030
Columbia University Medical Center
New York, United States, 10032
Simmons Comprehensive Cancer Center
Dallas, United States, 75390
Ronald Reagan UCLA Medical Center
Los Angeles, United States, 90095